Design and Analysis of Randomized Clinical Trials

Design and Analysis of Experiments

Volumn 3, Issue , 2012, Pages 165-211

  Wittes, Janet ^a,b   Yu, Zi Fan ^a  

^a University of Iowa   (United States)

^b AMERICAN STATISTICAL ASSOCIATION   (United States)

Author keywords

Confirmatory or phase 3 trials, bias, variability and masking; Failure time studies, and survival time; Randomized clinical trials, and statistical analysis

Indexed keywords

DESIGN AND ANALYSIS; RANDOMIZED CLINICAL TRIALS; SURVIVAL TIME;

EID: 84958594733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118147634.ch5     Document Type: Chapter

References (34)

1. Cutler, S.J. and F. Ederer (1958). Maximum utilization of the life table method in analyzing survival. J. Chronic Dis., 8, 699-712.
2. Ellenberg, S.S., T.R. Fleming, and D.L. DeMets (2002). Data Monitoring Committees in Clinical Trials. A Practical Perspective. New York: Wiley.
3. Fleming, T.R. (2008). Current issues in non-inferiority trials. Stat. Med., 27, 317-332.
4. Freedman, L.S. (1982). Tables of the number of patients required in clinical trials using the logrank test. Stat. Med., 1, 121-129.
5. Friedman, L.M., C.D. Furberg, and D.L. DeMets (1998). Fundamentals of Clinical Trials (3rd ed.). New York: Springer.
6. Furberg, C.D. and R.P. Byington (1983). What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. Circulation, 67, 98-101.
7. Gould, S.J. (1981). The Mismeasure of Man. New York: WW Norton and Company.
8. Greenwood, M. (1926). The natural duration of cancer. Reports on public health and medical subjects. Her Majesty's Stationery Office, London, 33, 1-26.
9. Halpern, J. and B.J. Brown (1993). A computer program for designing clinical trials with arbitrary survival curves and group sequential testing. Control. Clin. Trials, 14, 109-122.
10. Herson, J. (2009). Data and Safety Monitoring Committees in Clinical Trials. Boca Raton, FL: Chapman and Hall.
11. Jennison, C. and B.W. Turnbull (2002). Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall.
12. Kalbfleisch, J.D. and R.L. Prentice (2002). The Statistical Analysis of Failure Time Data (2nd ed.). New York: Wiley.
13. Kaplan, E.L. and P. Meier (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
14. Lachin, J. and M. Foulkes (1986). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics, 42, 507-519.
15. Lagakos, S.W., L.Y. Lim, and J.M. Robins (1990). Adjusting for early treatment termination in comparative clinical trials. Stat. Med., 9, 1417-1424.
16. Lakatos, E. (1986). Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control. Clin. Trials, 7, 189-199.
17. Lakatos, E. (1988). Sample size based on the log-rank statistics in complex clinical trials. Biometrics, 44, 229-241.
18. Lakatos, E. and K.K.G. Lan (1992). A comparison of sample size methods for the log rank statistics. Stat. Med., 11, 179-191.
19. Lan, K.K. and J. Witter (1986). Rank tests for survival analysis: A comparison by analogy with games. Biometrics, 41, 1063-1069.
20. Lee, Y.J., J.H. Ellenberg, D.G. Hirtz, and K.B. Nolan (1991). Analysis of clinical trials by treatment actually received: Is it really an option? Stat. Med., 10, 1595-1605.
21. Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemoter. Report, 50, 163-170.
22. Mantel, N. and W. Haenszel (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer. Inst., 22, 719-748.
23. Miller, R.G., Jr (1981). Survival Analysis. New York: Wiley.
24. Peduzzi, P., J. Wittes, K. Detre, and T. Holford (1993). Analysis as-randomized and the problem of non-adherence: An example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery. Stat. Med., 12, 1185-1195.
25. Peto, R. and J. Peto (1972). Asymptotically efficient rank invariant test procedures. J. R. Stat. Soc. A., 135, 185-198.
26. Piantadosi, S. (2005). Clinical Trials: A Methodological Perspective. New York: Wiley.
27. Pocock, S. (1983). Clinical Trials: A Practical Approach. New York: Wiley.
28. Proschan, M.A., K.K.G. Lan, and J.T. Wittes (2006). Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer.
29. Schoenfeld, D. (1983). Sample-size formula for the proportional-hazards regression model. Biometrics, 39, 499-503.
30. Shih, J. (1995). Sample size based on the log-rank statistic in complex clinical trials. Control. Clin. Trials, 16, 395-407.
31. Snappin, S. and Q. Jiang (2011). Analysis of multiple endpoints in clinical trials: It's time for the designations of primary, secondary and tertiary to go. Pharm. Stat, 10, 1-2. Published online in Wiley Interscience .
32. Yusuf, S., R. Collins, and R. Peto (1983). Why do we need some large, simple randomized trials? Stat. Med., 3, 409-420.
33. Yusuf, S., J. Wittes, J. Probstfield, and H. Tyroler (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA, 266, 93-98.
34. Zelen, M. (1993). Theory and practice of clinical trials. In: Cancer Medicine (3rd ed.). J.F. Holland, E. Frei III, R.C. Bast, D.W. Kufe, D. Morton, and R.R. Weichselbaum (eds.). Philadelphia: Lea and Febiger, pp. 299-313.